

Thanh-Trang T Vo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1763067/publications.pdf>

Version: 2024-02-01

12
papers

567
citations

1039406

9
h-index

1281420

11
g-index

12
all docs

12
docs citations

12
times ranked

1318
citing authors

#	ARTICLE	IF	CITATIONS
1	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. <i>Cell</i> , 2012, 151, 344-355.	13.5	294
2	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
3	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patientâ€™ derived xenograft mouse models. <i>Blood</i> , 2021, 137, 3365-3377.	0.6	47
4	BH3-Only Proteins and Their Effects on Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2010, 687, 49-63.	0.8	37
5	Targeting mTOR for the treatment of B cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1213-1228.	1.1	36
6	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. <i>Oncotarget</i> , 2015, 6, 2088-2100.	0.8	30
7	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. <i>Oncotarget</i> , 2015, 6, 35202-35217.	0.8	23
8	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. <i>Cancer Discovery</i> , 2015, 5, 697-700.	7.7	17
9	mTOR inhibition enhances efficacy of dasatinib in <i>ABL</i> -rearranged Ph-like B-ALL. <i>Oncotarget</i> , 2018, 9, 6562-6571.	0.8	15
10	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. <i>Blood</i> , 2016, 128, 2763-2763.	0.6	5
11	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. <i>Scientific Reports</i> , 2021, 11, 21689.	1.6	2
12	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2016, 128, 3969-3969.	0.6	0